Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with ALPPS for Liver Malignancy
NCT04996446Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Aug 2020
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in hepatocellular carcinoma (HCC), colorectal cancer (CRC), sponsored by Fudan University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
hepatocellular carcinoma (HCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04996446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996446.